How will your role help us transform hope into reality?
The Senior Director, Direct-to-Patient (DTP) Team Lead will be responsible for further establishing and maintaining a leadership position for Blueprint Medicines among the patient and caregiver community living with systemic mastocytosis (SM). Your strategic vision will ensure Blueprint Medicines has wholistic patient and caregiver engagement strategies, including groundbreaking patient marketing strategies and initiatives for SM and AYVAKIT (avapritinib), a potential multi-billion opportunity. Working collaboratively with cross-functional partners, you will represent the Voice of the Patient and be the driving force behind patient engagement strategies that not only speak to patients but also reinforces Blueprint Medicines Patient First mindset.
AYVAKIT's ongoing launch into Indolent Systemic Mastocytosis (ISM), provides a unique opportunity to build a new market and reach a patient community that had no therapeutic option until now that treated the underlying driver of disease. While ISM is a rare disease, it is extremely underdiagnosed with 9 years average time to diagnosis after seeing several types of medical specialists.
You will lead the Patient Marketing team, which is collectively responsible for creating and implementing strategies across disease awareness and product promotion to support personal and non-personal/digital promotion for patient audiences. Reporting to the Vice President, Commercial Strategy & Marketing, you will be a leader in both the marketing team and broader patient connect team across the organization. Working closely with cross-functional partners: Patient Advocacy, PR/Corp Communications, Regional Marketing, Commercial Operations, and US Market Access/Patient Services is crucial to brand success. Your collaborative efforts will ensure a cohesive and patient-centric approach across all patient touchpoints.
What will you do?
What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint?
At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators - the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success.
This is the place where the extraordinary becomes reality, and you could be part of it.
Patients are waiting. Are you ready to make the leap?
Equity, Diversity, Inclusion and Affirmative Action
At Blueprint Medicines, we foster a culture of equity, diversity and inclusion. A proud Equal Employment Opportunity and Affirmative Action employer, we consider all qualified applicants without regard to race, color, sex, gender identity or expression, sexual orientation, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, or any other characteristic protected under applicable law. We are also an E-Verify Employer. We will make reasonable accommodations, absent undue hardship, for qualified individuals with known disabilities. If you are an individual with a disability in need of an accommodation with the application or recruiting process, please reach out to TotalRewards@blueprintmedicines.com.
For more information, please see our , the EEO Know Your Rights Poster, as well as our Pay Transparency Statement.
Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing an approved medicine to people living with systemic mastocytosis (SM) in the U.S. and Europe. Additionally, we have a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including SM and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition.
#LI-Hybrid
#LI-AQ1